Shares of Moderna (MRNA) fell up to 25% on Thursday despite publishing positive clinical trial results for its cancer vaccine, illustrating how extreme market expectations can prompt a sharp selloff even after encouraging medical developments.
Key Takeaways
- Moderna (MRNA) stock dropped as much as 25% on Thursday following leaked partial trial data.
- The combination of Intismeran autogene and Merck’s Keytruda reduced melanoma recurrence or death risk by 42%.
- Moderna shares remain up over 530% in 2026, while Merck has gained nearly 41% year-to-date.
- Full Phase 3 trial results will be presented at the European Society for Medical Oncology (ESMO) conference this weekend.
High Expectations Trigger Selloff Despite Strong Efficacy
The selloff occurred after partial Phase 3 data leaked ahead of the formal release. According to the reported data, Moderna’s personalized cancer shot, Intismeran autogene, used alongside Merck’s immunotherapy Keytruda, demonstrated significant efficacy. Among trial participants, 82% of patients receiving the combination therapy were alive without disease recurrence at two years, compared to 70% of those treated with Keytruda alone. Furthermore, the combination therapy reduced the risk of distant cancer spread or death by 38%.
Despite these positive figures, Moderna shares slid while Merck dropped roughly 1%. Market analysts attributed the decline to previously priced-in optimism rather than fundamental flaws in the data. BMO Capital Markets analyst Evan Seigerman stated that the selloff likely reflected outsized market expectations leading up to the release rather than a negative assessment of the drug combination's effectiveness. Similarly, analysts at UBS categorized the trial results as strong, noting that high expectations explain the immediate market reaction. Even with Thursday's drop, Moderna stock remains up more than 530% for 2026 as of Thursday afternoon, while Merck is up nearly 41%.
Commercial Expansion and Manufacturing Bottlenecks
While the current trial focused exclusively on melanoma, researchers are actively testing the shot in other tumor types, including lung, bladder, and kidney cancers. Dean Li, president of Merck Research Laboratories, acknowledged that additional clinical work is required to prove efficacy across broader cancer indications. A successful expansion beyond melanoma would provide Moderna with a key commercial asset outside its existing pipeline of Covid-19, flu, and respiratory syncytial virus (RSV) vaccines.
However, commercialization faces practical manufacturing challenges. Producing each personalized dose relies on detailed tumor sequencing and currently takes up to six weeks. Speaking to CNBC, Merck CEO Robert Davis expressed confidence that the company can reduce this production timeframe to reach patients faster. Both companies noted that it remains too early to evaluate overall survival rates, with full Phase 3 data slated for presentation at the European Society for Medical Oncology (ESMO) conference this weekend.
Why It Matters
The market's reaction to Moderna's trial results underscores how valuation multiples can outpace clinical realities during aggressive market rallies, reminiscent of broader shifts seen in global equity market selloffs. While the 42% risk reduction validates the scientific potential of personalized mRNA treatments, commercial viability will depend heavily on solving manufacturing bottlenecks. Investors will closely monitor whether production timelines can be compressed sufficiently to scale the therapy across additional cancer indications.
